WallStSmart

Anheuser Busch Inbev NV ADR (BUD)vsCME Group Inc (CME)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Anheuser Busch Inbev NV ADR generates 804% more annual revenue ($60.96B vs $6.74B). CME leads profitability with a 63.3% profit margin vs 11.9%. BUD appears more attractively valued with a PEG of 1.78. CME earns a higher WallStSmart Score of 65/100 (C+).

BUD

Buy

63

out of 100

Grade: C+

Growth: 6.0Profit: 7.0Value: 4.7Quality: 5.0

CME

Buy

65

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 4.3Quality: 5.5
Piotroski: 1/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BUDOvervalued (-9.4%)

Margin of Safety

-9.4%

Fair Value

$70.63

Current Price

$79.89

$9.26 premium

UndervaluedFair: $70.63Overvalued

Intrinsic value data unavailable for CME.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BUD3 strengths · Avg: 8.3/10
Market CapQuality
$159.00B9/10

Large-cap with strong market position

Operating MarginProfitability
26.7%8/10

Strong operational efficiency at 26.7%

EPS GrowthGrowth
20.3%8/10

Earnings expanding 20.3% YoY

CME6 strengths · Avg: 9.0/10
Profit MarginProfitability
63.3%10/10

Keeps 63 of every $100 in revenue as profit

Operating MarginProfitability
69.8%10/10

Strong operational efficiency at 69.8%

Market CapQuality
$101.91B9/10

Large-cap with strong market position

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
21.3%8/10

Earnings expanding 21.3% YoY

Free Cash FlowQuality
$1.24B8/10

Generating 1.2B in free cash flow

Areas to Watch

BUD2 concerns · Avg: 4.0/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

Price/BookValuation
10.7x4/10

Trading at 10.7x book value

CME2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

PEG RatioValuation
4.862/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BUD

The strongest argument for BUD centers on Market Cap, Operating Margin, EPS Growth. Revenue growth of 12.0% demonstrates continued momentum.

Bull Case : CME

The strongest argument for CME centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 63.3% and operating margin at 69.8%. Revenue growth of 14.4% demonstrates continued momentum.

Bear Case : BUD

The primary concerns for BUD are PEG Ratio, Price/Book.

Bear Case : CME

The primary concerns for CME are Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

BUD profiles as a value stock while CME is a mature play — different risk/reward profiles.

BUD carries more volatility with a beta of 0.79 — expect wider price swings.

CME is growing revenue faster at 14.4% — sustainability is the question.

Monitor BEVERAGES - BREWERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CME scores higher overall (65/100 vs 63/100), backed by strong 63.3% margins and 14.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Anheuser Busch Inbev NV ADR

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.

CME Group Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

CME Group Inc. (Chicago Mercantile Exchange, Chicago Board of Trade, New York Mercantile Exchange, The Commodity Exchange) is an American global markets company. It is the world's largest financial derivatives exchange, and trades in asset classes that include agricultural products, currencies, energy, interest rates, metals, stock indexes and cryptocurrencies futures.

Visit Website →

Want to dig deeper into these stocks?